Geode Capital Management
LTRN icon

Geode Capital Management’s Lantern Pharma LTRN Stock Holding History

Geode Capital Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$429K Sell
102,819
-8,827
-8% -$25.9K ﹤0.01% 3663
2026
Q1 		$153K Buy
111,646
+14,904
+15% +$41.7K ﹤0.01% 4010
2025
Q4 		$293K Buy
96,742
+4,661
+5% +$17.4K ﹤0.01% 3779
2025
Q3 		$401K Buy
92,081
+190
+0.2% +$793 ﹤0.01% 3707
2025
Q2 		$290K Buy
91,891
+1,387
+2% +$4.68K ﹤0.01% 3747
2025
Q1 		$320K Buy
90,504
+3,531
+4% +$14.7K ﹤0.01% 3696
2024
Q4 		$278K Sell
86,973
-462
-0.5% -$1.58K ﹤0.01% 3794
2024
Q3 		$321K Buy
87,435
+1,088
+1% +$4.48K ﹤0.01% 3743
2024
Q2 		$403K Sell
86,347
-1,027
-1% -$6.18K ﹤0.01% 3649
2024
Q1 		$769K Sell
87,374
-7,662
-8% -$40.9K ﹤0.01% 3459
2023
Q4 		$407K Hold
95,036
– – ﹤0.01% 3692
2023
Q3 		$324K Buy
95,036
+5,010
+6% +$22.8K ﹤0.01% 3782
2023
Q2 		$508K Buy
90,026
+32,252
+56% +$167K ﹤0.01% 3633
2023
Q1 		$279K Hold
57,774
– – ﹤0.01% 3897
2022
Q4 		$348K Sell
57,774
-135
-0.2% -$676 ﹤0.01% 3835
2022
Q3 		$276K Buy
57,909
+345
+0.6% +$1.85K ﹤0.01% 4031
2022
Q2 		$328K Buy
57,564
+521
+0.9% +$3.11K ﹤0.01% 3985
2022
Q1 		$407K Hold
57,043
– – ﹤0.01% 4046
2021
Q4 		$455K Hold
57,043
– – ﹤0.01% 4108
2021
Q3 		$637K Buy
57,043
+1,564
+3% +$20.2K ﹤0.01% 3915
2021
Q2 		$809K Buy
55,479
+9,649
+21% +$149K ﹤0.01% 3709
2021
Q1 		$831K Buy
+45,830
New +$803K ﹤0.01% 3631

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Geode Capital Management's LTRN Position: Q2 2026 in Review

Geode Capital Management reduced its Lantern Pharma (LTRN) stake by 7.9% in Q2 2026, selling an estimated $25.9K and leaving 102,819 shares worth $429K. The position accounts for ﹤0.01% of the portfolio, ranked #3663.

Geode Capital Management first reported a position in LTRN in Q1 2021 and has held it in 22 quarters since. The position peaked at $831K in Q1 2021. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Geode Capital Management held 102,819 shares of Lantern Pharma worth $429K as of Q2 2026.
  • Geode Capital Management sold 8,827 Lantern Pharma shares in Q2 2026, an estimated $25.9K.
  • Lantern Pharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3663 holding.
  • Geode Capital Management first reported a position in Lantern Pharma in Q1 2021 and has held it in 22 quarters since.
  • Geode Capital Management's Lantern Pharma position peaked at $831K in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.